vs
Orthofix Medical Inc.（OFIX）与OMNICELL, INC.（OMCL）财务数据对比。点击上方公司名可切换其他公司
OMNICELL, INC.的季度营收约是Orthofix Medical Inc.的1.4倍（$309.9M vs $219.9M），OMNICELL, INC.净利率更高（3.7% vs -1.0%，领先4.7%），OMNICELL, INC.同比增速更快（14.9% vs 2.0%），OMNICELL, INC.自由现金流更多（$38.6M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 5.8%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Omnicell是总部位于美国加州山景城的跨国医疗科技企业，专注于为医院及各类医疗机构提供药品管理自动化系统，同时面向零售药房推出用药依从性包装与患者互动软件，旗下产品使用Omnicell及EnlivenHealth两大品牌。
OFIX vs OMCL — 直观对比
营收规模更大
OMCL
是对方的1.4倍
$219.9M
营收增速更快
OMCL
高出12.9%
2.0%
净利率更高
OMCL
高出4.7%
-1.0%
自由现金流更多
OMCL
多$21.8M
$16.8M
两年增速更快
OFIX
近两年复合增速
5.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $309.9M |
| 净利润 | $-2.2M | $11.4M |
| 毛利率 | 71.1% | 45.3% |
| 营业利润率 | 0.2% | 60.1% |
| 净利率 | -1.0% | 3.7% |
| 营收同比 | 2.0% | 14.9% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXOMCL
| Q1 26 | — | $309.9M | ||
| Q4 25 | $219.9M | $314.0M | ||
| Q3 25 | $205.6M | $310.6M | ||
| Q2 25 | $203.1M | $290.6M | ||
| Q1 25 | $193.6M | $269.7M | ||
| Q4 24 | $215.7M | $306.9M | ||
| Q3 24 | $196.6M | $282.4M | ||
| Q2 24 | $198.6M | $276.8M |
净利润OFIXOMCL
| Q1 26 | — | $11.4M | ||
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $5.5M | ||
| Q2 25 | $-14.1M | $5.6M | ||
| Q1 25 | $-53.1M | $-7.0M | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | $8.6M | ||
| Q2 24 | $-33.4M | $3.7M |
毛利率OFIXOMCL
| Q1 26 | — | 45.3% | ||
| Q4 25 | 71.1% | 41.5% | ||
| Q3 25 | 72.2% | 43.3% | ||
| Q2 25 | 68.7% | 43.9% | ||
| Q1 25 | 62.8% | 41.1% | ||
| Q4 24 | 69.0% | 46.2% | ||
| Q3 24 | 68.7% | 43.3% | ||
| Q2 24 | 67.8% | 41.3% |
营业利润率OFIXOMCL
| Q1 26 | — | 60.1% | ||
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | -8.3% | 2.7% | ||
| Q2 25 | -7.9% | 2.8% | ||
| Q1 25 | -25.2% | -4.3% | ||
| Q4 24 | -5.3% | 4.0% | ||
| Q3 24 | -9.6% | 2.3% | ||
| Q2 24 | -12.5% | 1.2% |
净利率OFIXOMCL
| Q1 26 | — | 3.7% | ||
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | 1.8% | ||
| Q2 25 | -6.9% | 1.9% | ||
| Q1 25 | -27.4% | -2.6% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | 3.1% | ||
| Q2 24 | -16.8% | 1.3% |
每股收益（稀释后）OFIXOMCL
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-0.05 | $-0.05 | ||
| Q3 25 | $-0.57 | $0.12 | ||
| Q2 25 | $-0.36 | $0.12 | ||
| Q1 25 | $-1.35 | $-0.15 | ||
| Q4 24 | $-0.76 | $0.34 | ||
| Q3 24 | $-0.71 | $0.19 | ||
| Q2 24 | $-0.88 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $239.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.3B |
| 总资产 | $850.6M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXOMCL
| Q1 26 | — | $239.2M | ||
| Q4 25 | $82.0M | $196.5M | ||
| Q3 25 | $62.9M | $180.1M | ||
| Q2 25 | $65.6M | $399.0M | ||
| Q1 25 | $58.0M | $386.8M | ||
| Q4 24 | $83.2M | $369.2M | ||
| Q3 24 | $30.1M | $570.6M | ||
| Q2 24 | $26.4M | $556.8M |
总债务OFIXOMCL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — |
股东权益OFIXOMCL
| Q1 26 | — | $1.3B | ||
| Q4 25 | $450.0M | $1.2B | ||
| Q3 25 | $442.5M | $1.2B | ||
| Q2 25 | $458.3M | $1.3B | ||
| Q1 25 | $458.3M | $1.3B | ||
| Q4 24 | $503.1M | $1.2B | ||
| Q3 24 | $525.9M | $1.2B | ||
| Q2 24 | $546.0M | $1.2B |
总资产OFIXOMCL
| Q1 26 | — | $2.0B | ||
| Q4 25 | $850.6M | $2.0B | ||
| Q3 25 | $832.6M | $1.9B | ||
| Q2 25 | $837.2M | $2.1B | ||
| Q1 25 | $823.1M | $2.2B | ||
| Q4 24 | $893.3M | $2.1B | ||
| Q3 24 | $867.9M | $2.3B | ||
| Q2 24 | $882.0M | $2.3B |
负债/权益比OFIXOMCL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $54.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $38.6M |
| 自由现金流率自由现金流/营收 | 7.6% | 12.5% |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 4.80× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $110.8M |
8季度趋势，按日历期对齐
经营现金流OFIXOMCL
| Q1 26 | — | $54.5M | ||
| Q4 25 | $27.7M | $30.4M | ||
| Q3 25 | $12.4M | $28.3M | ||
| Q2 25 | $11.6M | $42.8M | ||
| Q1 25 | $-18.4M | $25.9M | ||
| Q4 24 | $23.7M | $56.3M | ||
| Q3 24 | $11.7M | $22.8M | ||
| Q2 24 | $9.0M | $58.7M |
自由现金流OFIXOMCL
| Q1 26 | — | $38.6M | ||
| Q4 25 | $16.8M | $22.6M | ||
| Q3 25 | $2.5M | $18.5M | ||
| Q2 25 | $4.5M | $31.0M | ||
| Q1 25 | $-25.1M | $14.8M | ||
| Q4 24 | $15.2M | $47.2M | ||
| Q3 24 | $6.3M | $13.9M | ||
| Q2 24 | $-360.0K | $49.1M |
自由现金流率OFIXOMCL
| Q1 26 | — | 12.5% | ||
| Q4 25 | 7.6% | 7.2% | ||
| Q3 25 | 1.2% | 6.0% | ||
| Q2 25 | 2.2% | 10.7% | ||
| Q1 25 | -13.0% | 5.5% | ||
| Q4 24 | 7.0% | 15.4% | ||
| Q3 24 | 3.2% | 4.9% | ||
| Q2 24 | -0.2% | 17.8% |
资本支出强度OFIXOMCL
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 2.5% | ||
| Q3 25 | 4.8% | 3.1% | ||
| Q2 25 | 3.5% | 4.1% | ||
| Q1 25 | 3.5% | 4.1% | ||
| Q4 24 | 4.0% | 3.0% | ||
| Q3 24 | 2.7% | 3.1% | ||
| Q2 24 | 4.7% | 3.5% |
现金转化率OFIXOMCL
| Q1 26 | — | 4.80× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 5.18× | ||
| Q2 25 | — | 7.58× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | 15.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
OMCL
| Product revenues | $174.8M | 56% |
| Service revenues | $135.1M | 44% |
